• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4611063)   Today's Articles (6623)   Subscriber (49381)
For: Mavroudis D, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulias V. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 2000;11:1249-54. [PMID: 11106112 DOI: 10.1023/a:1008351310818] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
Number Cited by Other Article(s)
1
Riccardi A, Brugnatelli S, Danova M, Giordano M, Pugliese P, Luchena G, Grasso D, Trotti G, Bertè R, Pansini G, Tinelli C. Weekly Docetaxel and Gemcitabine following Docetaxel plus Epirubicin or Vinorelbine as First-Line Treatment of Metastatic Breast Cancer: Results of a Multicenter Phase II Study. TUMORI JOURNAL 2018;92:6-12. [PMID: 16683377 DOI: 10.1177/030089160609200102] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
2
Hénin E, Meille C, Barbolosi D, You B, Guitton J, Iliadis A, Freyer G. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. Breast Cancer Res Treat 2016;156:331-41. [PMID: 27002506 DOI: 10.1007/s10549-016-3760-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Accepted: 03/15/2016] [Indexed: 11/24/2022]
3
Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D. A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. Breast 2013;22:1171-7. [PMID: 24091128 DOI: 10.1016/j.breast.2013.08.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 07/01/2013] [Accepted: 08/29/2013] [Indexed: 12/21/2022]  Open
4
Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Am J Clin Oncol 2009;32:169-73. [PMID: 19307958 DOI: 10.1097/coc.0b013e31817eebdc] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
5
Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2009;21:48-54. [PMID: 19906761 DOI: 10.1093/annonc/mdp498] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
6
Abair T, Card P, O'Shaughnessy J. Highlights from: The 33rd European Society of Medical Oncology Congress: September 2008; Stockholm, Sweden. Clin Breast Cancer 2008. [DOI: 10.1016/s1526-8209(11)70808-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
7
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Br J Cancer 2008;98:1916-21. [PMID: 18493232 PMCID: PMC2441953 DOI: 10.1038/sj.bjc.6604409] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]  Open
8
Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 2007;97:1040-5. [PMID: 17940499 PMCID: PMC2360453 DOI: 10.1038/sj.bjc.6603982] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
9
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664-71. [PMID: 17116941 DOI: 10.1200/jco.2006.07.3916] [Citation(s) in RCA: 412] [Impact Index Per Article: 22.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]  Open
10
Nabholtz JM, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 2006;6:1073-94. [PMID: 15957963 DOI: 10.1517/14656566.6.7.1073] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
11
Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 2006;94:1233-6. [PMID: 16622454 PMCID: PMC2361414 DOI: 10.1038/sj.bjc.6603096] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]  Open
12
Nabholtz JM, Gligorov J. Docetaxel in the treatment of breast cancer: current experience and future prospects. Expert Rev Anticancer Ther 2006;5:613-33. [PMID: 16111463 DOI: 10.1586/14737140.5.4.613] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
13
Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients. J Clin Oncol 2005;23:413-21. [PMID: 15585753 DOI: 10.1200/jco.2005.09.161] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
14
Mavroudis D, Malamos N, Polyzos A, Kouroussis C, Christophilakis C, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V. Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology 2004;67:250-6. [PMID: 15557786 DOI: 10.1159/000081325] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2003] [Accepted: 04/23/2004] [Indexed: 11/19/2022]
15
Nabholtz JMA. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 2003;79 Suppl 1:S3-9. [PMID: 12868800 DOI: 10.1023/a:1024369220605] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
16
Morales S, Lorenzo A, Ramos M, Ballesteros P, Méndez M, Almanza C, Castellanos J, Moreno-Nogueira JA, Casal J, Lizón J, Oltra A, Frau A, Machengs I, Galán A, Belón J, Llorca C. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol 2003;53:75-81. [PMID: 14557896 DOI: 10.1007/s00280-003-0690-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2003] [Accepted: 07/11/2003] [Indexed: 11/26/2022]
17
Venturini M, Durando A, Garrone O, Colozza MA, Contu A, Stevani I, Genta F, Bighin C, Lambiase A, Del Mastro L. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 2003;97:1174-80. [PMID: 12599222 DOI: 10.1002/cncr.11203] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
18
Palmeri S, Leonardi V, Tamburo De Bella M, Morabito A, Vaglica M, Accurso V, Ferraù F, Failla G, Agostara B, Massidda B, Valenza R, Fanelli M, Gasparini G. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology 2002;63:205-12. [PMID: 12381898 DOI: 10.1159/000065466] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
19
Salminen E, Korpela J, Varpula M, Asola R, Varjo P, Pyrhönen S, Mali P, Hinkka S, Ekholm E. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study. Anticancer Drugs 2002;13:925-9. [PMID: 12394255 DOI: 10.1097/00001813-200210000-00004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
20
Yeo W, Mok TSK, Tse KK, Kwan WH, Lam KC, Ho WM, Chiu SKW, Chan ATC, Leung TWT, Mo FKF, Johnson PJ. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anticancer Drugs 2002;13:655-62. [PMID: 12172512 DOI: 10.1097/00001813-200207000-00013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
21
Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, Tolino G, Lambiase A, Baldini A, Canavese G, Rosso R. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol 2002;13:546-52. [PMID: 12056704 DOI: 10.1093/annonc/mdf056] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]  Open
22
Glück S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9:16-27. [PMID: 11965227 DOI: 10.1177/107327480200902s03] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]  Open
23
Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MFX, Jakesz R, Steger GG. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. Anticancer Drugs 2002;13:67-74. [PMID: 11914643 DOI: 10.1097/00001813-200201000-00008] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
24
Wolff AC. Systemic therapy. Curr Opin Oncol 2001;13:436-49. [PMID: 11673683 DOI: 10.1097/00001622-200111000-00005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA